-
-
-
-
-
-
-
BioCryst names Sandeep Menon as chief research and development officer
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
BioCryst receives antitrust clearance for Astria acquisition
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
-
-
-
-
-
-
-
Evercore ISI Downgrades BioCryst Pharma (BCRX) to In Line
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Presents New Data on the Long-term Efficacy and Safety of ORLADEYO
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
-
422,629 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

